NSAIDs, coxibs, and the intestine

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with significant gastrointestinal toxicity, including erosions, ulcers, and perforations in both the small and large intestines.
• NSAID-induced gastrointestinal lesions may contribute to anemia and complications like diverticular bleeding.
• While paracetamol is considered safer, some data suggest it may also possess toxicity.

Purpose of the Study:

• To evaluate the gastrointestinal safety profile of NSAIDs and explore the potential benefits of selective cyclooxygenase-2 (COX-2) inhibitors.
• To investigate the association between NSAID use and the development or relapse of inflammatory bowel diseases (IBD), specifically ulcerative colitis and Crohn's disease.

Main Methods:

• Review of existing literature on NSAID-induced gastrointestinal injuries.
• Analysis of data regarding the efficacy and safety of selective COX-2 inhibitors in IBD patients.
• Comparison of toxicity profiles between traditional NSAIDs, selective COX-2 inhibitors, and paracetamol.

Main Results:

• Selective COX-2 inhibitors demonstrate significantly reduced gastrointestinal toxicity compared to traditional NSAIDs.
• NSAID use is linked to the development or relapse of ulcerative colitis.
• The impact of NSAIDs and selective COX-2 inhibitors on Crohn's disease, particularly small bowel involvement, requires further investigation.
• Limited data exist on the effect of selective COX-2 inhibitors on ulcerative colitis relapse.

Conclusions:

• Selective COX-2 inhibitors represent a potentially safer therapeutic option for pain management in patients at risk of gastrointestinal complications.
• Further research is needed to clarify the role and safety of selective COX-2 inhibitors in managing inflammatory bowel diseases, especially ulcerative colitis relapse.